**The April 2026 DOJ/DEA order moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, following President Trump’s December 2025 executive order directing expedited rulemaking.** This partial rescheduling provides immediate regulatory relief for qualifying medical operators and research while preserving controls on illicit trafficking. A separate expedited administrative hearing on broader rescheduling of all marijuana to Schedule III opened June 29, 2026, at DEA headquarters and was scheduled to conclude by July 15. The proceeding gathers evidence on medical value and abuse potential to support or refine the 2024 notice of proposed rulemaking. Post-hearing, an administrative law judge recommendation and final agency action will determine full implementation timelines, subject to potential legal challenges such as those in the D.C. Circuit. Trader probabilities reflect the pace of these administrative steps, any delays in the final rule, and structural barriers like inter-agency coordination or court review before a complete shift from Schedule I occurs.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$791,987 KL.
Mar 31, 2026
September 30
14%
December 31
28%
$791,987 KL.
September 30
$0 KL.
14%
December 31
$182,416 KL.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The April 2026 DOJ/DEA order moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, following President Trump’s December 2025 executive order directing expedited rulemaking.** This partial rescheduling provides immediate regulatory relief for qualifying medical operators and research while preserving controls on illicit trafficking.
A separate expedited administrative hearing on broader rescheduling of all marijuana to Schedule III opened June 29, 2026, at DEA headquarters and was scheduled to conclude by July 15. The proceeding gathers evidence on medical value and abuse potential to support or refine the 2024 notice of proposed rulemaking. Post-hearing, an administrative law judge recommendation and final agency action will determine full implementation timelines, subject to potential legal challenges such as those in the D.C. Circuit. Trader probabilities reflect the pace of these administrative steps, any delays in the final rule, and structural barriers like inter-agency coordination or court review before a complete shift from Schedule I occurs.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Thị trường mở: Feb 7, 2026, 5:04 PM ET
Khối lượng
$791,987Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The April 2026 DOJ/DEA order moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, following President Trump’s December 2025 executive order directing expedited rulemaking.** This partial rescheduling provides immediate regulatory relief for qualifying medical operators and research while preserving controls on illicit trafficking.
A separate expedited administrative hearing on broader rescheduling of all marijuana to Schedule III opened June 29, 2026, at DEA headquarters and was scheduled to conclude by July 15. The proceeding gathers evidence on medical value and abuse potential to support or refine the 2024 notice of proposed rulemaking. Post-hearing, an administrative law judge recommendation and final agency action will determine full implementation timelines, subject to potential legal challenges such as those in the D.C. Circuit. Trader probabilities reflect the pace of these administrative steps, any delays in the final rule, and structural barriers like inter-agency coordination or court review before a complete shift from Schedule I occurs.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Khối lượng
$791,987Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The April 2026 DOJ/DEA order moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, following President Trump’s December 2025 executive order directing expedited rulemaking.** This partial rescheduling provides immediate regulatory relief for qualifying medical operators and research while preserving controls on illicit trafficking. A separate expedited administrative hearing on broader rescheduling of all marijuana to Schedule III opened June 29, 2026, at DEA headquarters and was scheduled to conclude by July 15. The proceeding gathers evidence on medical value and abuse potential to support or refine the 2024 notice of proposed rulemaking. Post-hearing, an administrative law judge recommendation and final agency action will determine full implementation timelines, subject to potential legal challenges such as those in the D.C. Circuit. Trader probabilities reflect the pace of these administrative steps, any delays in the final rule, and structural barriers like inter-agency coordination or court review before a complete shift from Schedule I occurs.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp